News
Living with LARS: Nutrition
Nutritionist Jill Haverstock discusses a variety of tips and suggestions to help you in your daily management of Lower Anterior...
Cancer Screening in Canada: Interview with Dr. Mel Borins
[:en]Dr. Mel Borins is a family practitioner based in Toronto, Ontario. He created the FIT test song to inspire more...
Interview: Jason from Man Up to Cancer
Jason Abramovitch is an early age onset stage 3b colon cancer survivor who received his diagnosis and underwent treatments in...
Acupressure and Auricular Therapy for Symptom Management
On December 3rd 2021, Physiotherapist Thi Tran gave a compelling session on the power of Acupressure and Auricular Therapy and...
Underrepresentation in cancer clinical trials
November 2021 Findings from a recent study published in JAMA Network Open highlighted the lack of representation of diverse racial...
First-line nivolumab plus low-dose ipilimumab for MSI-high/MMR-deficient mCRC
November 2021 Findings from phase II of the CheckMate-142 trial showed that the combination immunotherapy treatment of nivolumab (Opdivo) and...
Get social
Living with LARS: Nutrition
Nutritionist Jill Haverstock discusses a variety of tips and suggestions to help you in your daily management of Lower Anterior...
Cancer Screening in Canada: Interview with Dr. Mel Borins
[:en]Dr. Mel Borins is a family practitioner based in Toronto, Ontario. He created the FIT test song to inspire more...
Interview: Jason from Man Up to Cancer
Jason Abramovitch is an early age onset stage 3b colon cancer survivor who received his diagnosis and underwent treatments in...
Acupressure and Auricular Therapy for Symptom Management
On December 3rd 2021, Physiotherapist Thi Tran gave a compelling session on the power of Acupressure and Auricular Therapy and...
Underrepresentation in cancer clinical trials
November 2021 Findings from a recent study published in JAMA Network Open highlighted the lack of representation of diverse racial...
First-line nivolumab plus low-dose ipilimumab for MSI-high/MMR-deficient mCRC
November 2021 Findings from phase II of the CheckMate-142 trial showed that the combination immunotherapy treatment of nivolumab (Opdivo) and...






































